PubMed Health⌕ Search

PubMed · 15164230

Vertical reduction mammaplasty.

Abstract

The patients seeking our help for breast reduction are very often young and probably planning to have children later in their lives. Therefore it is most important to offer them a method of reduction mammaplasty that leaves as little scars and as much physiological function as possible. The vertical reduction mammaplasty as we perform it is a method that leaves normal sensibility in almost all cases, the possibility of lactation, little scarring and a pleasant form. The method can be used in all cases, ranging from mastopexy to reduction weights of over 2 kg of each breast. The vertical technique developed by Claude Lassus [1,2] and Madeleine Lejour [3,4,5,6] is a contemporary method of reduction that leaves few scars and conserves a maximum of physiological function. The method needs surgical skill and therefore it is not suitable for beginners in breast surgery. It is difficult to teach because it uses no patterns such as those of Strömbeck [7] or McKissock [8] but it gives the breasts a new form based on the anatomical circumstances and wishes of the patients. Due to some unfavorable results in the early beginning often caused by too long a caudal part of the breast or a dog-ear at the end of the vertical scar, we have added some modifications to the method. We've heard of the same problems from several colleagues who no longer perform this method in major reduction plasties. We have been using this technique in all cases of breast reductions or mastopexies for the past 8 years.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jan G Poëll. 2004-05-28. Vertical reduction mammaplasty.. https://doi.org/10.1007/s00266-003-2094-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.

The transcription factor Forkhead-box A1 (Foxa1), a member of the FOX class of transcription factors, has been implicated in the pathogenesis of lung, esophageal and prostate cancers. We have recently identified transcriptional activation of p27 by FOXA1. In this study, we analyzed the activities and expression pattern of FOXA1 in breast cancer. Forced expression of FOXA1 inhibited clonal growth of breast cancer cell lines, and FOXA1 levels inversely correlated with growth stimuli. In the estrogen receptor (ER)-positive MCF-7 cells, FOXA1 increased p27 promoter activity and inhibited the ER pathway activity. Analysis of FOXA1 expression in breast tissue arrays revealed significantly higher expression in pure ductal carcinomas in situ compared to invasive ductal carcinomas (IDC); and in IDC, high expression of FOXA1 was associated with favorable prognostic factors. Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer.

Breast↗

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

BACKGROUND: Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene "invasiveness" gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer.

Breast↗